This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1990 Feb;22(1):57-9.

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations

A B Jain¹, R Venkataramanan, E Cadoff, J J Fung, S Todo, A Krajack, T E Starzl

Affiliations

PMID: 1689900
PMCID: PMC2943675

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations

A B Jain et al. Transplant Proc. 1990 Feb.

. 1990 Feb;22(1):57-9.

Authors

A B Jain¹, R Venkataramanan, E Cadoff, J J Fung, S Todo, A Krajack, T E Starzl

Affiliation

¹ Department of Surgery, University of Pittsburgh, PA.

PMID: 1689900
PMCID: PMC2943675

No abstract available

PubMed Disclaimer

Figures

Fig 1 — Fig 1
Twenty-four hour trough plasma concentrations of FK 506 in relation to serum bilirubin following the first intravenous dose. Trough values tended to be higher when serum bilirubin was > 2 mg/dl.

Fig 2 — Fig 2
Typical pharmacokinetic profile following intravenous FK 506 administration in two patients with bilirubin 0.4 and 2.3 mg/dl. A slower fall in plasma concentration is noted after the distribution phase in the jaundiced patient.

Fig 3 — Fig 3
Pharmacokinetic profile of FK 506 after intravenous dosing on two separate occasions in the same patient. A rapid fall was noticed after the distribution phase as the liver function improved.

Fig 4 — Fig 4
Rise in daily trough levels of FK 506 as the hepatic function deteriorated. Three days after stopping FK 506, there was still a significant drug level in the blood plasma.

See this image and copyright information in PMC

Similar articles

Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine.
Venkataramanan R, Jain A, Warty VW, Abu-Elmagd K, Furakawa H, Imventarza O, Fung J, Todo S, Starzl TE. Venkataramanan R, et al. Transplant Proc. 1991 Feb;23(1 Pt 2):931-3. Transplant Proc. 1991. PMID: 1703355 Free PMC article. No abstract available.
Pharmacokinetics of FK 506: preclinical and clinical studies.
Venkataramanan R, Jain A, Cadoff E, Warty V, Iwasaki K, Nagase K, Krajack A, Imventarza O, Todo S, Fung JJ, et al. Venkataramanan R, et al. Transplant Proc. 1990 Feb;22(1):52-6. Transplant Proc. 1990. PMID: 1689899 Free PMC article. No abstract available.
Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil.
Jain AB, Hamad I, Zuckerman S, Zhang S, Warty VS, Fung JJ, Venkataramanan R. Jain AB, et al. Liver Transpl Surg. 1999 Mar;5(2):101-6. doi: 10.1002/lt.500050207. Liver Transpl Surg. 1999. PMID: 10071348
Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.
Staatz CE, Tett SE. Staatz CE, et al. Clin Pharmacokinet. 2004;43(10):623-53. doi: 10.2165/00003088-200443100-00001. Clin Pharmacokinet. 2004. PMID: 15244495 Review.
Clinical use of FK 506 in liver transplantation.
Klintmalm GB. Klintmalm GB. Transplant Proc. 1996 Apr;28(2):974-6. Transplant Proc. 1996. PMID: 8623484 Review.

See all similar articles

Cited by

Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients.
Sam WJ, Aw M, Quak SH, Lim SM, Charles BG, Chan SY, Ho PC. Sam WJ, et al. Br J Clin Pharmacol. 2000 Dec;50(6):531-41. doi: 10.1046/j.1365-2125.2000.00288.x. Br J Clin Pharmacol. 2000. PMID: 11136292 Free PMC article. Clinical Trial.
Sensitivity of estimated tacrolimus population pharmacokinetic profile to assumed dose timing and absorption in real-world data and simulated data.
Williams ML, Weeks HL, Beck C, Birdwell KA, Van Driest SL, Choi L. Williams ML, et al. Br J Clin Pharmacol. 2022 Jun;88(6):2863-2874. doi: 10.1111/bcp.15218. Epub 2022 Jan 27. Br J Clin Pharmacol. 2022. PMID: 34997625 Free PMC article.
A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.
Andreu F, Colom H, Elens L, van Gelder T, van Schaik RHN, Hesselink DA, Bestard O, Torras J, Cruzado JM, Grinyó JM, Lloberas N. Andreu F, et al. Clin Pharmacokinet. 2017 Aug;56(8):963-975. doi: 10.1007/s40262-016-0491-3. Clin Pharmacokinet. 2017. PMID: 28050888
Strategy of FK 506 therapy in liver transplant patients: effect of graft function.
Abu-Elmagd KM, Fung JJ, Alessiani M, Jain A, Takaya S, Venkataramanan R, Warty VS, Shannon W, Todo S, Tzakis A, et al. Abu-Elmagd KM, et al. Transplant Proc. 1991 Dec;23(6):2771-4. Transplant Proc. 1991. PMID: 1721272 Free PMC article. No abstract available.
Effects of liver disease on pharmacokinetics. An update.
Rodighiero V. Rodighiero V. Clin Pharmacokinet. 1999 Nov;37(5):399-431. doi: 10.2165/00003088-199937050-00004. Clin Pharmacokinet. 1999. PMID: 10589374 Review.

See all "Cited by" articles

References

1. Starzl TE, Todo S, Fung JJ, et al. Lancet. 1989;2:1000. - PMC - PubMed
1. Venkataramanan R, Jain AB, Cadoff E, et al. Transplant Proc. (this issue) - PMC - PubMed
1. Hoffman AF. Gastroenterology. 1966;50:56. - PubMed
1. Tamura K, Kobayashi M, Hashimoto K, et al. Transplant Proc. 1987;19(suppl 6):23. - PubMed
1. Cadoff E, Venkataramanun R, Krajack A, et al. Transplant Proc. (this issue)

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Medical
- MedlinePlus Health Information